All lobbying filings

SPLITOAK STRATEGIES LLC

Lobbying for ALNYLAM PHARMACEUTICALS, INC. · Biopharmaceutical company

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · Massachusetts · House · Senate · $60,000.00 income · posted Oct 20, 2025

Official filing document

Bills named in this filing 3

HR 1672
Maintaining Investments in New Innovation Act
HR 946
ORPHAN Cures Act
S 1862
ORPHAN Cures Act

Lobbying activity 1

Medicare/Medicaid

RNA interference scientific advancements and rare diseases; differentiation of genetically-targeted therapies; H.R. 1672, Maintaining Investments in New Innovation Act; H.R. 946/S. 1862, ORPHAN Cures Act; P.L. 119-21

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.